Capsulution and EBARA Expand Co-operation: Pre-Clinical Studies in the Focus of Product Development
21 September 2006
BERLIN, September 21st, 2006 – EBARA Corp. of Japan and Capsulution NanoScience AG of Berlin recently finalised the expansion of their co-operation that began in 2005. As such, the two companies are now also collaborating to develop new products for the improved and goal-oriented delivery of pharmaceutical substances.
In order to achieve this goal, the two companies have selected concrete active agents whose delivery properties are to be improved using Capsulution’s nanocapsules or complexes. At the foreground of development is the time-controlled release of the active agents. Such developments are of great benefit to customers, as they simplify the delivery of medications, reduce side effects and thus increase therapeutic success.
In particular, products are to be adapted especially to the needs of the Japanese pharmaceutical market. Presently the new active agent formulas are to undergo testing to determine their effects on living organisms in the context of pre-clinical experiments in Japan. The costs for further development are divided equally between the two companies.
“With the expansion of our co-operation we will achieve a new quality in our collaborative work with EBARA. Both partners are convinced that visible results can be achieved in as little as 12 months on the basis of our shared know-how and the increased mutual trust”, says Alexander Herrmann, Chief Financial Officer.
The decision to expand co-operation represents an important step for both partners in the successful marketing of Capsulution’s LBL Technology® and the manufacturing equipment developed especially for EBARA (LBL-Units). The first prototype of the LBL-Unit already began operation late last year.
